A better understanding of the response and side effect of clozapine use

Recruiting

• Conditions: Schizophrenia,schizophreniform and schizoaffective disorderClozapine, psychotic disorders

• Registration Number: NL-OMON20290
• Lead Sponsor: niversity Medical Center Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

he/she is about to initiate CLZ (i.e. he/she has an indication to start CLZ treatment according to the treating physician and he/she is willing to start on CLZ)

-he/she has received a diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder or psychosis not otherwise specified.

Exclusion Criteria

- admission to a psychiatric unit involuntarily in the context of an ‘inbewaringstelling’ (IBS)

- a history of Parkinson’s disease

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reponse and the development of ADRs after clozapine intake. We think this is influenced by methylation patterns and gene expression

Secondary Outcome Measures

Name	Time	Method
We measure non-genetic factors such as smoking, cannabis use, duration of illness etc., because we think these influence treatment outcome (ADRs+response) as well. In addition, we use the data with our other protocol (NTR 5257) to create a prediction model for clozapine response and side effects.